INS and metabolic syndrome: This reversibility of changes in β-cell function (total insulin content) induced by simvastatin is highly important, implying that a therapy withdrawal or change of dyslipidemia medications might warrant the prevention of new-onset T2D or the remission of statin-induced diabetes in clinical settings.